Gelonghui, April 23 | Baiyang Pharmaceutical (301015.SZ) announced that the company collaborates with AstraZeneca Business Consulting (Wuxi) Co., Ltd., CICC Capital Operation Co., Ltd., Shandong New Kinetic Energy Fund Management Co., Ltd., Qingdao Innovation Investment Co., Ltd., Qingdao Hi-Tech Industry Development Parent Fund Partnership (Limited Partnership), Wuxi AstraZeneca CICC Venture Capital Partnership (Limited Partnership), Jinan Hi-Tech Finance Investment Co., Ltd., Yinfeng Finance (Beijing) Investment Management Co., Ltd., and Tianjin Jiashan Industrial Development Investment Co., Ltd. Invested in the establishment of AstraZeneca CICC Qingdao Healthcare Venture Capital Fund (limited partnership). AstraZeneca Business Consulting (Wuxi) Co., Ltd. and CICC Capital Operation Co., Ltd. are general partners and executive partners of the partnership, and the other investors are limited partners of the partnership. The total amount of pledged capital of the partnership was RMB 100,000 million. As a limited partner, the company pledged 50 million yuan with its own capital, accounting for 5% of the total pledged capital. The partnership focuses on investment projects in the healthcare sector (including but not limited to biomedicine and biotechnology) in China, and gives priority to supporting projects determined by the Shandong Provincial Committee and Provincial Government and major project bank projects for the conversion of old and new kinetic energy in Shandong Province.